Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
4(44%)
Results Posted
133%(4 trials)

Phase Distribution

Ph phase_2
2
22%
Ph phase_1
5
56%
Ph phase_3
2
22%

Phase Distribution

5

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
5(55.6%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

9

all time

Status Distribution
Active(6)
Completed(3)

Detailed Status

Active, not recruiting3
Completed3
Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (55.6%)
Phase 22 (22.2%)
Phase 32 (22.2%)

Trials by Status

not_yet_recruiting222%
recruiting111%
active_not_recruiting333%
completed333%

Recent Activity

4 active trials
Showing 5 of 9
recruitingphase_1

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
active_not_recruitingphase_1

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

NCT05307705
not_yet_recruitingphase_2

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098
active_not_recruitingphase_3

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054
completedphase_1

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

NCT05444556
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05768139Phase 1

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Recruiting
NCT05307705Phase 1

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Active Not Recruiting
NCT07287098Phase 2

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Not Yet Recruiting
NCT05514054Phase 3

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Active Not Recruiting
NCT05444556Phase 1

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Completed
NCT05509816Phase 1

A Study of Imlunestrant (LY3484356) in Healthy Women

Completed
NCT05440344Phase 1

A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

Completed
NCT07191717Phase 2

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Not Yet Recruiting
NCT04975308Phase 3

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active Not Recruiting

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9